Cash Flow Statement

Acquisitions Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Rxo (RXO) Acquisitions (2024 - 2025)

Rxo's Acquisitions history spans 2 years, with the latest figure at $10.0 million for Q1 2025.

For Q1 2025, Acquisitions changed N/A year-over-year to $10.0 million; the TTM value through Dec 2025 reached $10.0 million, down 99.02%, while the annual FY2025 figure was $10.0 million, 99.02% down from the prior year.
Acquisitions reached $10.0 million in Q1 2025 per RXO's latest filing, down from $1.0 billion in the prior quarter.
In the past five years, Acquisitions ranged from a high of $1.0 billion in Q3 2024 to a low of $10.0 million in Q1 2025.